tered to children in Alberta, relative to same-day administration of separate MMR and varicella (MMR+V) vaccines. A secondary objective was to determine if children considered to be at "high risk" for seizures were at increased risk for febrile seizures following administration of the combination vaccine.
Methods

Study setting and data sources
Alberta has a population of 4.1 million and an annual birth cohort of over 50 000. 9 The province has a publicly funded, universally available health care system. Registration in the health insurance plan is mandatory for all residents, and the plan covers more than 99% of the population. Each person registered receives a unique numeric identifier that can be used to assess health service use and to link health records at the individual level. 10 Routine recommended childhood vaccinations in Alberta are provided at no cost to the recipient and are administered by public health nurses in community-based clinics, according to the schedule set by the Alberta Ministry of Health (see Appendix 1, available at www.cmaj.ca/lookup /suppl/doi:10.1503/cmaj.140078/-/DC1). Individual-level vaccination data are submitted by each health zone to the provincial immunization repository. The repository includes data on specific vaccines administered to all children resident in Alberta, except First Nations children living on reserves, who receive their vaccinations through federally administered programs, and children in the border town of Lloydminster, who receive public health services from the province of Saskatchewan. The repository has data submission guidelines and business rules that promote the completeness and quality of data submissions, such as flagging mismatches between vaccine name and lot number.
Seizure events that involve presentation to the health care system in Alberta can be ascertained from 3 administrative databases: the physician claims database, an electronic fee-for-service system to which all physicians submit billing information; the ambulatory care reporting system, which includes emergency department visits; and the hospital discharge abstracts database. Previous epidemiologic studies [11] [12] [13] [14] have found that these data sources have a high level of completeness and validity. Physicians must submit diagnostic codes (up to 3 per visit) to be reimbursed under the feefor-service insurance plan, and relatively few Alberta physicians (< 7%) are on alternate payment plans, compared with other Canadian provinces. 15 The ambulatory care and hospital dis- [17] [18] [19] [20] Coding did not change during the study period.
Because we compared seizure incidence in the periods before and immediately after vaccination, we assumed that any increase in frequency of febrile seizure after vaccination was related to the vaccine. We linked seizure data to vaccination data through deterministic matching, using unique lifetime identifiers. Ethics consent for this study was obtained from the University of Calgary Conjoint Health Research Ethics Board.
Data analysis
For each vaccine administered, we compared the incidence of seizures in the 42-day "observation period" following administration (comparable with clinical trials of Priorix-Tetra and the postlicensure study of ProQuad 2, 6, 21 ) and the 7-to 10-day "peak period" (when previous studies have indicated that febrile seizure risk is expected to be highest 2, 22 ) with the incidence in the 42 days preceding vaccination (control period) using a riskinterval analysis. 23 To confirm that the defined peak period was valid in our study, we conducted a sensitivity analysis, looking at 9 different risk windows ([5, 6, 7 days] × [10, 11, 12 days]). 24 To avoid counting repeat visits for the same seizure event, we considered only the first seizure within the overall period of observation (from 42 days before to 42 days after vaccination). We conducted Poisson regression, controlling for age and calendar year. We calculated and compared the absolute risk of seizures for MMRV and MMR+V to determine any excess risk of seizures from MMRV. All analyses were performed with SAS version 9.2 (SAS Institute).
The primary data analysis included all children in the cohort. The secondary analysis was conducted to determine if high-risk children exhibited a differentially higher risk of seizures following MMRV relative to MMR+V. We defined "highrisk" children (as per previous studies 19, 25 ) as those with a personal history of febrile seizure; seizure disorder; central nervous system injury, infection or neoplasm; encephalopathy; or a progressive, evolving or unstable neurologic condition (as identified from physician claims, emergency department visits or hospital discharges using applicable codes [see Appendix 2, available at www.cmaj. ca /lookup /suppl/doi:10.1503/cmaj .140078 /-/DC1]).
We were unable to identify family history of seizures. Table 1) . The difference in age distributions for the groups receiving MMRV and MMR+V was statistically significant but not clinically meaningful: 91.4% and 92.6% of children, respectively, received the vaccine between ages 12 and 15 months. Four percent of the children in the cohort were considered at high risk for seizures because of prior medical conditions.
Results
Our
We observed a notable increase in seizure incidence in the 7-10 days after either vaccine combination (Figure 1 ), which fits with the biologically plausible period for febrile seizures after a measles-containing vaccine. 2, 22 The incidence after MMR+V peaked at 2.2 seizures per 10 000 doses, whereas the incidence after MMRV was higher, at 5.8 seizures per 10 000 doses. Our sensitivity analysis confirmed the validity of the 7-to 10-day postvaccine "peak period" for seizure incidence. The rate of seizures was notably higher in the high-risk group than in the rest of the cohort, both before and after vaccination ( Table 1) .
The unadjusted and adjusted relative risks for seizures after MMRV and MMR+V, and the ratio between these risks, are reported in Table 2 . In the adjusted analysis, there was no differentially increased risk after MMRV compared with MMR+V in the 0-to 42-day observation window (relative risk [RR] 1.21, 95% confidence interval [CI] 0.93-1.58), but the risk was elevated in the 7-to 10-day peak period (RR 1.99, 95% CI 1.30-3.05) ( Table 2 ). The risk of seizures was differentially elevated with MMRV in the low-risk group (RR 2.27, 95% CI 1.48-3.49) but not the highrisk group (RR 1.30, 95% CI 0.60-2.79). During the 7-to 10-day peak period, the excess absolute risk of seizures resulting from administration of the MMRV vaccine relative to MMR+V was 3.52 seizures per 10 000 doses administered (Table 3) .
Interpretation
During the 7-to 10-day peak period, the risk of febrile seizures among children receiving their first dose of MMRV was double that for sameday administration of the separate vaccines. This translates to an additional 3.52 seizures per 10 000 doses administered, or 1 excess seizure for every 2841 doses administered. Whether this increase is of practical significance is uncertain, as the threshold for acceptable risk may differ among parents, clinicians and policy-makers. The risk after MMRV relative to MMR+V in the low-risk group was essentially similar to that in the full cohort. The risk in the high-risk group was not differentially higher for MMRV, which may be explained by the already-high baseline incidence of seizures in this group. The lack of a differentially increased risk after MMRV in the high-risk group is reassuring and suggests that no additional criteria are needed to guide immunization of this group.
The 2010 statement of the National Advisory Committee on Immunization regarding MMRV 4 noted that the lack of evidence of an increase in risk for febrile seizure with MMRV may be due to study sample sizes that were too small to detect a difference. This highlights the need for population-based postlicensure studies of less common adverse events, such as febrile seizures. One such study recently conducted in Germany Note: CI = con dence interval, MMRV = measles-mumps-rubella-varicella vaccine, MMR+V = measles-mumps-rubella vaccine plus varicella vaccine, RR = relative risk. *Adjusted for calendar year and age. †Only 4 cases of postvaccination seizure were identi ed in the high-risk group in 2011, lower than expected given that about 10 cases were identi ed in each of the other years. Thus, 2011 was treated as an outlier but was kept in the model by including a separate parameter for this year and its effect on the high-risk group within the risk interval.
all causes, including after ProQuad vaccine, 3 are known to be less common in children 4-6 years of age than in younger children. 4 Our finding that seizures were twice as common after the first dose of MMRV is consistent with results of the study of ProQuad in the US, 2 in which the relative risk of seizures was 1.98 (95% CI 1.43-2.73) in the 7 to 10 days after administration. These findings resulted in the US Advisory Committee on Immunization Practices withdrawing its preference for use of the combination vaccine for the first dose. 26 This body instead advises immunization providers and parents to consider the benefits and risks of each option before choosing. If there is no parental preference, it recommends that separate MMR and varicella vaccine be administered for the first dose in children 12-47 months of age and that MMRV be given to older children or second-dose recipients. Perhaps a similar recommendation is appropriate for Priorix-Tetra.
Our finding of no difference in seizure risk between MMRV and MMR+V for the high-risk group concurs with the finding of Klein and colleagues 2 regarding ProQuad. Although they did not assess RR, they reported that the proportion of children with a personal history of seizures who had postvaccination febrile seizures was similar for those who received MMRV and those who received MMR+V.
Strengths and limitations
This study had the advantage of using a large population-based cohort in a universal health care system. We were able to capture all vaccination events and medically attended seizure events for the entire population, thus avoiding the sampling bias that may occur with private health insurance data sources, which often exclude lower-income individuals. 27, 28 Although our study did not capture seizures for which no medical care was sought, we think it likely that most seizure events in children under the age of 2 years would cause sufficient parental concern to prompt access of health care services. Also, although we did not conduct chart reviews to confirm febrile seizures, seizure events were measured consistently both before and after vaccination for the 2 vaccine types, so calculation of the RRs should have been unbiased. When Klein and colleagues 2 conducted such chart reviews in their study, the RR changed from 1.98 to 2.04.
Because administration of MMR+V was replaced by MMRV in 2010, our comparison is susceptible to a historical effect. In addition to adjusting for calendar year in our analysis, we examined the baseline incidence of seizures by calendar year (see Appendix 3, available at www .cmaj.ca/lookup/suppl/doi:10.1503/cmaj.140078/ -/DC1) and found no historical trend. Also, although the 13-valent pneumococcal conjugate vaccine was added to the 12-month vaccination schedule in 2010 (see Appendix 1), the risk window for febrile seizures after this vaccine and its predecessor, the 7-valent pneumococcal conjugate vaccine (both inactivated vaccines), is less than 7 days after vaccination 20, [29] [30] [31] and thus would not confound our finding of an increased risk in days 7 to 10.
It is possible that limiting our cohort to vaccinated children might have influenced the rate of seizures in the prevaccine period if unvaccinated children had a different incidence of seizures than their vaccinated peers (i.e., a "healthy vaccinee effect"). Although it is possible that such an effect might have altered the RR of seizures for both MMRV and MMR+V, it would not have affected the ratio between the 2 (as both groups would be equally biased), which was our primary measure of interest. The available population-level data did not permit identification of antipyretic use, which might have altered incidence of high fever and subsequent febrile seizures.
Conclusion
Combining MMR and varicella into a single vaccine decreases pain for children and distress for parents, thus addressing common barriers to vaccine uptake, 6, [32] [33] [34] and may improve vaccine coverage levels and decrease immunization delivery costs. 35 These potential benefits must be balanced by the increased risk (albeit small) of febrile seizures with the combination vaccine. Febrile seizures are typically self-limiting and rarely have long-term effects, 36 but they can be extremely distressing for parents, may precipitate acute care visits and may undermine confidence in immu- Note: MMRV = measles-mumps-rubella-varicella vaccine, MMR+V = measles-mumps-rubella vaccine plus varicella vaccine.
nization programs. 4, 37 It is a matter for debate whether the choice of separate versus combination vaccine is a policy decision or a choice for parents to make in consultation with their vaccination provider. If MMRV continues to be offered for first-dose administration, it might be advisable to counsel parents regarding antipyretic use if children experience a fever within the peak risk period.
